EcoDrugPlus

Adenosine Receptor A2b-Like

Ensembl ID : ENSOKIG00005041671
Gene Symbol: LOC109871728
3 Cross references
184 Possible Orthologues:

Adenosine Receptor A2b-Like

Ensembl ID : ENSOKIG00005038126
Gene Symbol: LOC109872643
3 Cross references
191 Possible Orthologues:

Adrenoceptor Alpha 1b

Ensembl ID : ENSOKIG00005038137
Gene Symbol: ADRA1B
3 Cross references
190 Possible Orthologues:

Adrenoceptor Alpha 1b

Ensembl ID : ENSOKIG00005002911
Gene Symbol: ADRA1B
3 Cross references
190 Possible Orthologues:

Adrenoceptor Alpha 1b

Ensembl ID : ENSOKIG00005013118
Gene Symbol: ADRA1B
3 Cross references
185 Possible Orthologues:

Adrenoceptor Alpha 1d

Ensembl ID : ENSOKIG00005021065
Gene Symbol: ADRA1D
3 Cross references
187 Possible Orthologues:

Adrenoceptor Alpha 1d

Ensembl ID : ENSOKIG00005025944
Gene Symbol: ADRA1D
3 Cross references
188 Possible Orthologues:

Adrenoceptor Alpha 2a

Ensembl ID : ENSOKIG00005026391
Gene Symbol: ADRA2A
3 Cross references
170 Possible Orthologues:

Adrenoceptor Alpha 2a

Ensembl ID : ENSOKIG00005045779
Gene Symbol: ADRA2A
3 Cross references
153 Possible Orthologues:

Adrenoceptor Alpha 2a

Ensembl ID : ENSOKIG00005049141
Gene Symbol: ADRA2A
1 Cross references
153 Possible Orthologues:

Adrenoceptor Alpha 2a

Ensembl ID : ENSOKIG00005021247
Gene Symbol: ADRA2A
3 Cross references
171 Possible Orthologues:

Adrenoceptor Alpha 2b

Ensembl ID : ENSOKIG00005029442
Gene Symbol: ADRA2B
1 Cross references
143 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).